Paper35348191
Ricolinostat enhances adavosertib‑induced mitotic catastrophe in TP53‑mutated head and neck squamous cell carcinoma cells.
Miyake K and 6 others. Int J Oncol, 2022. Cited by 21 papers, by iCite.
Cite this record
ConductScience Library. Ricolinostat enhances adavosertib‑induced mitotic catastrophe in TP53‑mutated head and neck squamous cell carcinoma cells. Papers, record 35348191. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35348191
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Ricolinostat enhances adavosertib‑induced mitotic catastrophe in TP53‑mutated head and neck squamous cell carcinoma cells.
- PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Head and Neck Neoplasms | Major topic |
| Tumor Suppressor Protein p53 | Major topic |
| Apoptosis | |
| Cell Line, Tumor | |
| Humans | |
| Hydroxamic Acids | |
| Pyrazoles | |
| Pyrimidines | |
| Pyrimidinones | |
| Squamous Cell Carcinoma of Head and Neck |
Source PubMed
References56
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 18201278 | Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs. | Cancer Sci | 2008 | https://conductscience.org/library/papers/18201278 | PubMed |
| 2 | 23520471 | Wee1 inhibition by MK-1775 leads to tumor inhibition and enhances efficacy of gemcitabine in human sarcomas. | PLoS One | 2013 | https://conductscience.org/library/papers/23520471 | PubMed |
| 3 | 21798893 | The mutational landscape of head and neck squamous cell carcinoma. | Science | 2011 | https://conductscience.org/library/papers/21798893 | PubMed |
| 4 | 15077146 | Cell death by mitotic catastrophe: a molecular definition. | Oncogene | 2004 | https://conductscience.org/library/papers/15077146 | PubMed |
| 5 | 2175676 | The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. | Cell | 1990 | https://conductscience.org/library/papers/2175676 | PubMed |
| 6 | 29954437 | Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint. | J Exp Clin Cancer Res | 2018 | https://conductscience.org/library/papers/29954437 | PubMed |
| 7 | 19402126 | The histone deacetylase inhibitor LBH589 inhibits expression of mitotic genes causing G2/M arrest and cell death in head and neck squamous cell carcinoma cell lines. | J Pathol | 2009 | https://conductscience.org/library/papers/19402126 | PubMed |
| 8 | 27880943 | TP53 mutations, expression and interaction networks in human cancers. | Oncotarget | 2017 | https://conductscience.org/library/papers/27880943 | PubMed |
| 9 | 7626804 | The Wee1 protein kinase regulates T14 phosphorylation of fission yeast Cdc2. | Mol Biol Cell | 1995 | https://conductscience.org/library/papers/7626804 | PubMed |
| 10 | 22553330 | Activation of cap-dependent translation by mucosal human papillomavirus E6 proteins is dependent on the integrity of the LXXLL binding motif. | J Virol | 2012 | https://conductscience.org/library/papers/22553330 | PubMed |
| 11 | 22957056 | Depletion of HDAC6 enhances cisplatin-induced DNA damage and apoptosis in non-small cell lung cancer cells. | PLoS One | 2012 | https://conductscience.org/library/papers/22957056 | PubMed |
| 12 | 32958072 | A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target. | J Hematol Oncol | 2020 | https://conductscience.org/library/papers/32958072 | PubMed |
| 13 | 32611648 | A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer. | Clin Cancer Res | 2020 | https://conductscience.org/library/papers/32611648 | PubMed |
| 14 | 19010849 | Ubiquitin proteasome system stress underlies synergistic killing of ovarian cancer cells by bortezomib and a novel HDAC6 inhibitor. | Clin Cancer Res | 2008 | https://conductscience.org/library/papers/19010849 | PubMed |
| 15 | 21037108 | Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents. | Proc Natl Acad Sci U S A | 2010 | https://conductscience.org/library/papers/21037108 | PubMed |
| 16 | 30662800 | Antitumor activity of the novel HDAC inhibitor CUDC-101 combined with gemcitabine in pancreatic cancer. | Am J Cancer Res | 2018 | https://conductscience.org/library/papers/30662800 | PubMed |
| 17 | 15916966 | HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. | Mol Cell | 2005 | https://conductscience.org/library/papers/15916966 | PubMed |
| 18 | 24013427 | Wee1 kinase as a target for cancer therapy. | Cell Cycle | 2013 | https://conductscience.org/library/papers/24013427 | PubMed |
| 19 | 34286042 | An Image-based Assay for High-throughput Analysis of Cell Proliferation and Cell Death of Adherent Cells. | Bio Protoc | 2018 | https://conductscience.org/library/papers/34286042 | PubMed |
| 20 | 22766642 | Overexpression of histone deacetylase 6 contributes to accelerated migration and invasion activity of hepatocellular carcinoma cells. | Oncol Rep | 2012 | https://conductscience.org/library/papers/22766642 | PubMed |
Cited by17
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 21 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42939551 | Advances in p53 Therapies for Oral Squamous Cell Carcinoma: A Literature Review. | Curr Issues Mol Biol | 2026 | https://conductscience.org/library/papers/42939551 | PubMed |
| 42469385 | A Rho GTPase-related gene signature predicts prognosis and reveals an immunosuppressive microenvironment in lung adenocarcinoma: an integrated analysis of bulk and single-cell RNA sequencing data. | Sci Rep | 2026 | https://conductscience.org/library/papers/42469385 | PubMed |
| 41940897 | Unraveling the molecular landscape: an overview on gene expression, epigenetic alterations, and therapeutic challenges in head and neck squamous cell carcinoma. | Mol Genet Genomics | 2026 | https://conductscience.org/library/papers/41940897 | PubMed |
| 40468445 | WNT3 promotes chemoresistance to oxaliplatin in oral squamous cell carcinoma via regulating ABCG2 expression. | Cell Biosci | 2025 | https://conductscience.org/library/papers/40468445 | PubMed |
| 39800760 | Combinatorial functionomics identifies HDAC6-dependent molecular vulnerability of radioresistant head and neck cancer. | Exp Hematol Oncol | 2025 | https://conductscience.org/library/papers/39800760 | PubMed |
| 39301607 | Advanced Human Papillomavirus-Negative Head and Neck Squamous Cell Carcinoma: Unmet Need and Emerging Therapies. | Mol Cancer Ther | 2024 | https://conductscience.org/library/papers/39301607 | PubMed |
| 39199381 | The Function of H2A Histone Variants and Their Roles in Diseases. | Biomolecules | 2024 | https://conductscience.org/library/papers/39199381 | PubMed |
| 39063958 | Selective HDAC6 Inhibition Has the Potential for Anti-Cancer Effect in Renal Cell Carcinoma. | J Pers Med | 2024 | https://conductscience.org/library/papers/39063958 | PubMed |
| 38702756 | Targeting histone deacetylases in head and neck squamous cell carcinoma: molecular mechanisms and therapeutic targets. | J Transl Med | 2024 | https://conductscience.org/library/papers/38702756 | PubMed |
| 38684944 | HIST3H2A promotes the progression of prostate cancer through inhibiting cell necroptosis. | BMC Cancer | 2024 | https://conductscience.org/library/papers/38684944 | PubMed |
| 38539518 | TP53 and/or BRCA1 Mutations Based on CtDNA Analysis as Prognostic Biomarkers for Primary Triple-Negative Breast Cancer. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/38539518 | PubMed |
| 37834095 | Bortezomib Is Effective in the Treatment of T Lymphoblastic Leukaemia by Inducing DNA Damage, WEE1 Downregulation, and Mitotic Catastrophe. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37834095 | PubMed |
| 36338767 | Targeting DNA damage response as a potential therapeutic strategy for head and neck squamous cell carcinoma. | Front Oncol | 2022 | https://conductscience.org/library/papers/36338767 | PubMed |
| 36076996 | Targeting HDAC6 to Overcome Autophagy-Promoted Anti-Cancer Drug Resistance. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/36076996 | PubMed |
| 36036883 | HDAC6: A unique HDAC family member as a cancer target. | Cell Oncol (Dordr) | 2022 | https://conductscience.org/library/papers/36036883 | PubMed |
| 36012642 | Evaluation of the Therapeutic Potential of Histone Deacetylase 6 Inhibitors for Primary and Metastatic Uveal Melanoma. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/36012642 | PubMed |
| 35652048 | Role of Selective Histone Deacetylase 6 Inhibitor ACY-1215 in Cancer and Other Human Diseases. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/35652048 | PubMed |
Genes18
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/35348191
GET https://conductscience.org/api/papers/v1/35348191/references?page=2